MCK - McKesson Corporation
| Previous Close | 170.78 |
| Open | 169.75 |
| Bid | 170.00 x 800 |
| Ask | 171.00 x 1200 |
| Day's Range | 168.48 - 172.18 |
| 52 Week Range | 110.52 - 172.18 |
| Volume | 3,720,919 |
| Avg. Volume | 1,688,077 |
| Market Cap | 30.248B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.97 |
| Earnings Date | May 05, 2020 - May 10, 2020 |
| Forward Dividend & Yield | 1.64 (0.98%) |
| Ex-Dividend Date | Feb 27, 2020 |
| 1y Target Est | 168.50 |
- Zacks
Here's Why Momentum Investors Will Love McKesson (MCK)
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Is McKesson (MCK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Investopedia
Drug Distributor Stocks in Focus on Opioid Settlement News
Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.
- GuruFocus.com
Andreas Halvorsen's Top 5 Buys in the 4th Quarter
Viking leader releases quarterly portfolio Continue reading...
- TheStreet.com
U.S. States Reject Drug Wholesalers' Opioid-Settlement Offer
The 21 U.S. state attorneys general who sued opioid makers rejected a settlement offer of $18 billion from three drugmakers that were looking to end the litigation against them, a media report says.
- Zacks
MCK vs. COO: Which Stock Should Value Investors Buy Now?
MCK vs. COO: Which Stock Is the Better Value Option?
Reuters21 states reject $18 bln offer from U.S. distributors to settle opioid lawsuits - WSJ
Twenty one states reject an $18 billion settlement offer from three major drug distributors to resolve litigation over their alleged role in the opioid crisis, the Wall Street Journal reported on Friday, citing a letter sent to the companies' law firms earlier this week. The dissenting states want the companies - AmeriSourceBergen Corp, McKesson Corp and Cardinal Health Inc - to pay between $22 billion and $32 billion, WSJ reported https://on.wsj.com/37kSRkA, citing a person familiar with a matter. McKesson is focused on finalizing a global settlement structure that would provide billions of dollars in immediate funding and relief to states and local communities, a company spokesman said in an emailed statement.
- MarketWatch
Drug wholesaler stocks falls after WSJ report that states rejected opioid settlement offer
Shares of drug wholesalers, who have held talks to settle opioid litigation, sank in morning trading Friday, after The Wall Street Journal reported that 21 states had rejected an $18 billion settlement offer. Shares of AmerisourceBergen Corp. dropped 2.4%, Cardinal Health Inc. shed 2.5%, McKesson Corp. lost 1.4% and Johnson & Johnson fell 0.4%. In comparsion, the S&P 500 inched up less than 0.1%. The WSJ report, which cited a person familiar with the matter, said the dissenting states want the wholesalers to pay between $22 billion and $32 billion, for their alleged roles in contributing to the opioid crisis.
- Zacks
McKesson Corporation Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor McKesson Corporation
- Zacks
Has McKesson (MCK) Outpaced Other Medical Stocks This Year?
Is (MCK) Outperforming Other Medical Stocks This Year?
- Schaeffer's Investment Research
Options Traders Play the MCK, SPCE, and LYFT Stock Rallies
The shares of MCK, SPCE, and LYFT are gaining today
- Barrons.com
The Dow Is Up 52 Points Even Though the Coronavirus Death Toll Is Still Rising
All three major U.S. stock indexes were in positive territory, marking a recovery from losses early in the day.
- GuruFocus.com
Wall Street Opens Higher Monday
Loews jumps on fourth quarter results Continue reading...
- Zacks
5 Stocks to Watch as Fatalities Due to Coronavirus Rise
Coronavirus is ravaging China and several other countries. With no cure yet, health officials are struggling to stop its spread. Demand for medical supplies like masks is up manifold.
- Business Wire
McKesson Launches Exchange Offer to Split-Off Its Interest in Change Healthcare
McKesson Corporation (NYSE:MCK) today announced the commencement of an exchange offer for the split-off of its wholly-owned subsidiary, PF2 SpinCo, Inc. ("SpinCo"), which will hold all of McKesson’s interest in Change Healthcare LLC ("Change Healthcare"), as part of McKesson’s previously announced agreement with Change Healthcare Inc. (Nasdaq:CHNG) ("Change") to merge SpinCo with and into Change.
- American City Business Journals
First Look: CoverMyMeds starts second HQ building in Franklinton (slideshow)
CoverMyMeds has started work on the second building for its Franklinton headquarters two years ahead of schedule. Here's the peek at the design changes from its fraternal twin.
- Thomson Reuters StreetEvents
Edited Transcript of MCK earnings conference call or presentation 4-Feb-20 1:00pm GMT
Q3 2020 McKesson Corp Earnings Call
- American City Business Journals
Three years after merger, McKesson to part ways with Change Healthcare
As part of the deal, McKesson as an entity will cease to own any part of Change and the company will give up its three seats on Change’s board of directors.
- Zacks
McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss
McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.
- Zacks
McKesson (MCK) Tops Q3 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of 7.63% and -0.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- MarketWatch
McKesson's Q3 revenue rises
Shares of McKesson Corp. were up 0.69% in premarket trading on Tuesday after the drug distributor said its adjusted earnings beat expectations for the quarter. Earnings tumbled to $191 million, or $1.03 per share, in the third quarter of 2020, compared with $470 million, or $2.40 per share, in the same quarter a year ago. Adjusted earnings came in at $685 million, or $3.81 per share for the third quarter of 2020, compared to $664 million, or $3.40 per share, in the same quarter a year ago. The FactSet consensus was $636 million, or $3.50 per share. The distributor reported a 5% increase in revenue, to $59.1 billion in the third quarter of 2020, up from $56.2 billion in the third quarter of 2019. The company attributed the increase to growth in the U.S. pharmaceutical and specialty solutions business. The FactSet consensus was $59.4 billion. The company affirmed its EPS guidance for 2020, saying it expects EPS between $14.60 and $14.80. It had updated the guidance range of $14.00 and $14.60 in January. McKesson's stock has gained about 9% over the past year, compared with the S&P 500 , which is up 20%.
- Business Wire
McKesson Reports Fiscal 2020 Third Quarter Results
McKesson Corporation (NYSE:MCK) today reported results for the third quarter ended December 31, 2019.
- ACCESSWIRE
McKesson Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 4, 2020 / McKesson Corp. (NYSE:MCK) will be discussing their earnings results in their 2020 Third Quarter Earnings to be held on February 4, 2020 at 8:00 AM Eastern ...
